In response to the recent tragedy involving the deaths of 20 children in Madhya Pradesh linked to Coldrif cough syrup manufactured by Sresan Pharmaceuticals, Tamil Nadu Health Secretary Senthil Kumar confirmed that the company’s license has been suspended. He highlighted that the state government has intensified inspections across Tamil Nadu and implemented stringent measures against the company for violating safety norms. Senthil Kumar stated, "The state authority conducted inspections on Sresan Pharmaceuticals and imposed fines for violations. Due to lapses over the past two years, corrective actions have been enforced. The government continues to carry out periodic and intensive inspections to ensure compliance." Addressing concerns raised by the recent Comptroller and Auditor General (CAG) report, which identified gaps in Tamil Nadu’s drug testing protocols, the Health Secretary assured that criminal proceedings are underway against the company. Furthermore, the government has bolstered its regulatory framework by recruiting 90 additional drug inspectors to enhance monitoring and enforcement. The developments follow the arrest of S Ranganathan, owner of Sresan Pharmaceuticals, by Madhya Pradesh police. The arrest is part of the investigation into the deaths of children in Madhya Pradesh and Rajasthan, allegedly caused by the toxic cough syrup. Earlier, the Supreme Court dismissed a Public Interest Litigation (PIL) seeking a Central Bureau of Investigation (CBI) probe into the incident. Chief Justice of India BR Gavai-led bench declined the plea, noting that state governments, including Tamil Nadu and Madhya Pradesh, are actively addressing the issue. Advocate Vishal Tiwari, the petitioner, had argued for a centralized investigation citing prior issues with adulterated medicines and a lack of coordinated response. The Tamil Nadu government’s decisive actions underscore its commitment to drug safety and protecting public health in the wake of this tragic incident.